FDA expands eligibility for second booster shot for older and immunocompromised individuals
Moderately and severely immunocompromised individuals between the ages of 12 and 17 may receive a second booster of the Pfizer vaccine, while people 18 and older may receive either Pfizer or Moderna. This allows immunocompromised individuals to now receive a fifth total dose of the COVID-19 vaccine.
CDC data continue to show the importance of getting vaccinated and boosted, if eligible, to protect against severe outcomes of COVID-19, including hospitalization and death. During the recent Omicron surge, boosted individuals were 7 times less likely to be hospitalized and 21 times less likely to die from COVID-19 compared to those who were unvaccinated.
"We welcome the news that many more Louisianans who may be at high risk of severe outcomes from COVID-19 now have more options to protect themselves," said State Health Officer Dr. Joseph Kanter. "We do not know what the future holds and continue to monitor circulating variants, but thankfully, our COVID-19 trends are better and we have more tools at our disposal than ever before, and that includes vaccines and boosters."
In addition, adults who received a primary vaccine and booster dose of Johnson & Johnson’s Janssen COVID-19 vaccine at least 4 months ago may now receive a second booster dose using an mRNA COVID-19 vaccine (Pfizer or Moderna).
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.